Compositions and methods for treating eye infections and disease
AssigneeUniversity of Virginia Patent Foundation
InventorGordon W. LAURIE
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.
Claims20
A method of treating dry eye, the method comprising:
- topically administering a therapeutically effective amount of a sterile, aqueous, topical pharmaceutical composition to an ocular surface,
- wherein the sterile aqueous topical pharmaceutical composition comprises:
- a peptide, or a pharmaceutically acceptable salt thereof,
- wherein the peptide, or pharmaceutically acceptable salt thereof, has an amino acid sequence consisting of SEQ ID NO:
- 5,
- wherein the C-terminus of the peptide is amidated,
- wherein the N-terminus of the peptide is acylated, and
- a pharmaceutically acceptable aqueous carrier.
A method of treating dry eye comprising:
- topically administering a therapeutically effective amount of a pharmaceutical composition to an ocular surface,
- wherein the pharmaceutical composition comprises:
- a peptide, or a pharmaceutically acceptable salt thereof,
- wherein the peptide, or pharmaceutically acceptable salt thereof, has an amino acid sequence consisting of SEQ ID NO:
- 7,
- wherein the C-terminus of the peptide is amidated,
- wherein the N-terminus of the peptide is acylated, and
- a pharmaceutically acceptable carrier.
A method of treating dry eye in a subject, comprising:
- detecting a 25 kDa syndecan-1 fragment in tears of a subject;
- and
- administering to an eye of the subject a therapeutically effective amount of a pharmaceutical composition comprising:
- a peptide, or a pharmaceutically acceptable salt thereof,
- wherein the peptide, or pharmaceutically acceptable salt thereof, has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 5, 6, 7, 8, or a derivative thereof,
- wherein the derivative thereof differs from SEQ ID NO:
- 5, 6, 7 or 8 by one or two amino acid substitutions, and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.